Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (831)	10/13/2003 6:03:54 PM
From: The Dodgy Ticker	Respond to of 1005

OT: "A" certainly seems to be the most popular beginning letter for the names of biotech companies. Maybe they think that if it worked for Amgen...

To: keokalani'nui who wrote (831)	10/15/2003 9:44:59 AM
From: nigel bates	Respond to of 1005

One more... WASHINGTON, Oct 15 (Reuters) - Biopharmaceutical company GTX Inx., which is working on treatments for men's health problems, filed on Wednesday with the Securities and Exchange Commission (News - Websites) to raise $86 million in an initial public offering. The Memphis, Tennessee-based company plans to use the net proceeds to fund clinical trials and other research and development activities and for general corporate purposes. The preliminary prospectus did not disclose the number of common shares or the price range. That information is expected in future filings. GTX has applied for a Nasdaq listing under the symbol "GTXI" (Nasdaq:GTXI - News) and the underwriters are Goldman Sachs, SG Cowen and Lazard.